Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Liminatus Pharma ( (LIMN) ) has provided an update.
On February 27, 2026, Liminatus Pharma’s board amended the company’s bylaws to lower the stockholder meeting quorum from a majority to one-third of the voting power of outstanding shares entitled to vote. The change, immediately effective upon board approval, applies both to overall stockholder meetings and to any required class or series votes, and allows meetings lacking a quorum to be adjourned until sufficient participation is reached.
The board also authorized submission of the quorum reduction amendment to stockholders for ratification at the next annual meeting, while retaining authority under Delaware law to keep the change in place even if shareholders do not approve it. The move is likely aimed at easing the logistical and voting hurdles of convening valid meetings, potentially shifting the balance of corporate control mechanics and influencing how easily management can secure stockholder decisions.
More about Liminatus Pharma
Liminatus Pharma, Inc. operates in the biopharmaceutical sector, though this disclosure focuses on its corporate governance framework rather than specific drug candidates or therapeutic areas. The company is organized under Delaware law, and its stock is held by a broad base of shareholders whose voting power determines corporate actions at annual and special meetings.
Average Trading Volume: 8,679,988
Technical Sentiment Signal: Sell
Current Market Cap: $9.05M
For detailed information about LIMN stock, go to TipRanks’ Stock Analysis page.